{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:05:13Z","timestamp":1786118713444,"version":"build-2736575974"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,3]]},"DOI":"10.1097\/cco.0b013e3280148a43","type":"journal-article","created":{"date-parts":[[2007,3,23]],"date-time":"2007-03-23T03:48:41Z","timestamp":1174621721000},"page":"128-135","source":"Crossref","is-referenced-by-count":8,"title":["Blood or marrow transplantation for mantle cell lymphoma"],"prefix":"10.1097","volume":"19","author":[{"given":"Yvette L","family":"Kasamon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20210128","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/oxfordjournals.annonc.a059155","article-title":"Patterns of survival in mantle cell lymphoma","volume":"6","author":"Zucca","year":"1995","journal-title":"Ann Oncol"},{"key":"R3-11-20210128","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1182\/blood-2002-08-2476","article-title":"Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen)","volume":"102","author":"Gianni","year":"2003","journal-title":"Blood"},{"key":"R4-11-20210128","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/annonc\/mdh069","article-title":"Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis","volume":"15","author":"Mangel","year":"2004","journal-title":"Ann Oncol"},{"key":"R5-11-20210128","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/cncr.21313","article-title":"Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma","volume":"104","author":"Thieblemont","year":"2005","journal-title":"Cancer"},{"key":"R6-11-20210128","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1182\/blood-2004-10-3883","article-title":"Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network","volume":"105","author":"Dreyling","year":"2005","journal-title":"Blood"},{"key":"R7-11-20210128","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1034\/j.1600-0609.2003.00093.x","article-title":"Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant","volume":"71","author":"Andersen","year":"2003","journal-title":"Eur J Haematol"},{"key":"R8-11-20210128","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1046\/j.1365-2141.2003.04140.x","article-title":"Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries","volume":"120","author":"Vandenberghe","year":"2003","journal-title":"Br J Haematol"},{"key":"R9-11-20210128","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1182\/blood-2005-07-2845","article-title":"Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma","volume":"107","author":"Pott","year":"2006","journal-title":"Blood"},{"key":"R10-11-20210128","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1002\/cncr.11838","article-title":"Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score","volume":"98","author":"Khouri","year":"2003","journal-title":"Cancer"},{"key":"R11-11-20210128","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1182\/blood.V104.11.8.8","article-title":"Nordic Mantle Cell Lymphoma (MCL) Project: prolonged follow-up of 86 patients treated with BEAM\/BEAC PBSCT confirms that addition of high-dose ara-C and rituximab to CHOP induction in vivo purging with rituximab increases clinical and molecular response rates, PCR-neg. grafts, failure-free, relapse-free and overall survival [abstract].","volume":"104","author":"Geisler","year":"2004","journal-title":"Blood"},{"key":"R12-11-20210128","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.bbmt.2004.09.007","article-title":"Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma","volume":"11","author":"Kasamon","year":"2005","journal-title":"Biol Blood Marrow Transplant"},{"key":"R13-11-20210128","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1023\/A:1008380527502","article-title":"Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy","volume":"10","author":"Khouri","year":"1999","journal-title":"Ann Oncol"},{"key":"R14-11-20210128","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1182\/blood.V104.11.894.894","article-title":"Autologous vs allogeneic cell transplantation for mantle cell lymphoma (MCL): outcomes over a 10-year period at City of Hope [abstract].","volume":"104","author":"Popplewell","year":"2004","journal-title":"Blood"},{"key":"R15-11-20210128","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1093\/annonc\/mdi107","article-title":"Hematopoietic stem cell transplantation in mantle cell lymphoma","volume":"16","author":"Ganti","year":"2005","journal-title":"Ann Oncol"},{"key":"R16-11-20210128","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/ajh.20646","article-title":"Efficacy of high-dose therapy and hematopoietic stem cell transplantation for mantle cell lymphoma","volume":"81","author":"Laudi","year":"2006","journal-title":"Am J Hematol"},{"key":"R17-11-20210128","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1083-8791(01)70016-X","article-title":"Allogeneic bone marrow transplantation in patients with sensitive low-grade lymphoma or mantle cell lymphoma","volume":"7","author":"Berdeja","year":"2001","journal-title":"Biol Blood Marrow Transplant"},{"key":"R18-11-20210128","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.1998.16.1.13","article-title":"High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission","volume":"16","author":"Freedman","year":"1998","journal-title":"J Clin Oncol"},{"key":"R19-11-20210128","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1023\/A:1008278605751","article-title":"Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma","volume":"8","author":"Ketterer","year":"1997","journal-title":"Ann Oncol"},{"key":"R20-11-20210128","first-page":"1275","article-title":"Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study","volume":"89","author":"Lefrere","year":"2004","journal-title":"Haematologica"},{"key":"R21-11-20210128","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.leu.2402406","article-title":"Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study","volume":"16","author":"Lefrere","year":"2002","journal-title":"Leukemia"},{"key":"R22-11-20210128","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.thj.6200007","article-title":"The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients","volume":"1","author":"Dreger","year":"2000","journal-title":"Hematol J"},{"key":"R23-11-20210128","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1080\/10428190290026286","article-title":"Autologous stem cell transplantation in patients with mantle cell lymphoma","volume":"43","author":"Oinonen","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"R24-11-20210128","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJM198706113162401","article-title":"High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma","volume":"316","author":"Philip","year":"1987","journal-title":"N Engl J Med"},{"key":"R25-11-20210128","doi-asserted-by":"crossref","first-page":"7555","DOI":"10.1200\/jco.2006.24.18_suppl.7555","article-title":"Impact of rituximab on outcome of autologous transplantation for mantle cell lymphoma [abstract].","volume":"24","author":"Naing","year":"2006","journal-title":"J Clin Oncol"},{"key":"R26-11-20210128","doi-asserted-by":"crossref","first-page":"7511","DOI":"10.1200\/jco.2006.24.18_suppl.7511","article-title":"Mantle cell lymphoma (MCL): induction therapy with hyperCVAD\/high-dose methotrexate and cytarabine (M-C) (\/ rituximab) improves results of autologous stem cell transplant in first remission [abstract].","volume":"24","author":"Vose","year":"2006","journal-title":"J Clin Oncol"},{"key":"R27-11-20210128","doi-asserted-by":"crossref","first-page":"4407","DOI":"10.1200\/JCO.2003.05.501","article-title":"Nonablative allogeneic stem-cell transplantation for advanced\/recurrent mantle-cell lymphoma","volume":"21","author":"Khouri","year":"2003","journal-title":"J Clin Oncol"},{"key":"R28-11-20210128","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1182\/blood.V104.11.2260.2260","article-title":"Reduced intensity allogeneic stem cell transplantation for mantle cell lymphoma is associated with substantial late transplant related mortality and a poor outcome in patients with chemosensitive disease [abstract].","volume":"104","author":"Robinson","year":"2004","journal-title":"Blood"},{"key":"R29-11-20210128","doi-asserted-by":"crossref","first-page":"7013","DOI":"10.1200\/JCO.2005.01.1825","article-title":"High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine","volume":"23","author":"Romaguera","year":"2005","journal-title":"J Clin Oncol"},{"key":"R30-11-20210128","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","article-title":"Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma","volume":"328","author":"Fisher","year":"1993","journal-title":"N Engl J Med"},{"key":"R31-11-20210128","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/sj.bmt.1701400","article-title":"High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience","volume":"22","author":"Milpied","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"R32-11-20210128","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1182\/blood.V90.10.4212","article-title":"Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease","volume":"90","author":"Andersen","year":"1997","journal-title":"Blood"},{"key":"R33-11-20210128","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1182\/blood.V83.10.3068.3068","article-title":"Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML","volume":"83","author":"Deisseroth","year":"1994","journal-title":"Blood"},{"key":"R34-11-20210128","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0140-6736(93)92560-G","article-title":"Gene-marking to trace origin of relapse after autologous bone-marrow transplantation","volume":"341","author":"Brenner","year":"1993","journal-title":"Lancet"},{"key":"R35-11-20210128","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1182\/blood.V106.11.2089.2089","article-title":"Favorable influence of pretransplant rituximab but not of high-dose ara-C in upfront autologous stem cell transplantation (SCT) for mantle cell lymphoma (MCL) [abstract].","volume":"106","author":"Rieger","year":"2005","journal-title":"Blood"},{"key":"R36-11-20210128","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1182\/blood.V106.11.2078.2078","article-title":"Long term remission in follicular lymphoma (FL) and mantle cell lymphoma (MCL) with rituximab consolidation after high-dose chemotherapy and autologous stem cell transplantation: extended follow-up of a multicenter phase II study [abstract].","volume":"106","author":"Brugger","year":"2005","journal-title":"Blood"},{"key":"R37-11-20210128","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood.V108.11.2741.2741","article-title":"Phase II study of high dose outpatient cyclophosphamide and rituximab, without stem cell support, for low grade and mantle cell lymphoma [abstract].","volume":"108","author":"Swinnen","year":"2005","journal-title":"Blood"},{"key":"R38-11-20210128","first-page":"863","article-title":"Effect of two cyclophosphamide derivatives on hemopoietic progenitor cells and pluripotential stem cells","volume":"12","author":"Porcellini","year":"1984","journal-title":"Exp Hematol"},{"key":"R39-11-20210128","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1182\/blood.V99.9.3158","article-title":"High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma","volume":"99","author":"Gopal","year":"2002","journal-title":"Blood"},{"key":"R40-11-20210128","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/blood.V106.11.681.681","article-title":"New transplant strategies utilizing radioimmunotherapy (RIT) based regimens to reduce relapse in high risk mantle cell lymphoma (MCL) [abstract].","volume":"106","author":"Krishnan","year":"2005","journal-title":"Blood"},{"key":"R41-11-20210128","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1182\/blood-2005-03-1310","article-title":"A phase 1\/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma","volume":"106","author":"Nademanee","year":"2005","journal-title":"Blood"},{"key":"R42-11-20210128","first-page":"482a","article-title":"Does transplantation improve outcome in mantle cell lymphoma (MCL)? A study from the EBMT [abstract]","volume":"96","author":"Vandenberghe","year":"2000","journal-title":"Blood"},{"key":"R43-11-20210128","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1182\/blood.V99.1.75","article-title":"Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies","volume":"99","author":"Corradini","year":"2002","journal-title":"Blood"},{"key":"R44-11-20210128","doi-asserted-by":"crossref","first-page":"3535","DOI":"10.1182\/blood-2004-06-2275","article-title":"Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma","volume":"104","author":"Maris","year":"2004","journal-title":"Blood"},{"key":"R45-11-20210128","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1182\/blood-2004-03-1105","article-title":"Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma","volume":"104","author":"Morris","year":"2004","journal-title":"Blood"},{"key":"R46-11-20210128","doi-asserted-by":"crossref","first-page":"4310","DOI":"10.1182\/blood-2001-11-0107","article-title":"Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation","volume":"100","author":"Robinson","year":"2002","journal-title":"Blood"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CCO.0b013e3280148a43","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:35:55Z","timestamp":1786034155000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001622-200703000-00011"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0b013e3280148a43","relation":{},"ISSN":["1040-8746"],"issn-type":[{"value":"1040-8746","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3]]}}}